The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy

Transplantation

Volumn 75, Issue 6, 2003, Pages 772-780

  Saunders, R N ^a   Bicknell, G R ^a   Nicholson, M L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 3; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; GELATINASE A; RAPAMYCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT REJECTION; LEUKOPENIA; MALE; MORPHOMETRICS; NEPHROTOXICITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA;

ADULT; CHRONIC DISEASE; COLORING AGENTS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS; STAINING AND LABELING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037468719     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200303270-00008     Document Type: Article

References (64)

1. Isoniemi HM, Krogerus L, Von Willebrand E, Taskinen E, Ahonen J, Hayry P. Histopathological findings in well functioning long-term renal allografts. Kidney Int 1992; 41: 151.
2. Paul LC. Chronic allograft nephropathy: an update. Kidney Int 1999; 56: 783.
3. Kasiske BL, Kalil RS, Lee HS, Rao KV. Histopathological findings associated with a chronic decline in renal allograft function: Kidney Int 1991; 80: 514.
4. Jain S, Furness PN, Nicholson ML. The role of TGFβ in chronic renal allograft nephropathy. Transplantation 2000; 69: 1759.
5. Furness PN. Extracellular matrix of the kidney. J Clin Pathol 1996; 49: 355.
6. Strutz F. Novel aspects of renal fibrogenesis. Neph Dial Transplant 1998; 10: 1526.
7. Terasaki PI, Cecka JM, Cho Y. Overview. In: Terasaki PI, ed. Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1990 pp 1-10.
8. Grinyo JM. Progress with cyclosporin-sparing regimens. Transplant Proc 1999; 31: 11S.
9. Hollander AA, Van Saase JL, Kootte AM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610.
10. Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine dose reduction in renal transplant recipients with histologically proven chronic cyclosporine nephrotoxicity. Transplantation 1998; 65: 661.
11. Weir MR, Anderson L, Fink JC, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706.
12. Hueso M, Bover J, Seron D, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 1727.
13. Nicholson ML, Jain SJ, Metcalfe MS, White SA, Furness PN. Chronic allograft nephropathy: a prospective randomized controlled trial of cyclosporine dose reduction with or without mycophenolate mofetil [Abstract]. Transplantation 2000; 69: S227.
14. Sehgal SN. Rapamune (sirolimus, rapamycin). An overview and mechanism of action. J Ther Drug Monit 1995; 17: 660.
15. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. The Rapamune U.S. Study Group. Lancet 2000; 356: 194.
16. Groth CG, Backman L, Morales J, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 1036.
17. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
18. MacDonald AS. A worldwide phase III randomized controlled safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. The Rapamune Global Study Group. Transplantation 2001; 71: 271.
19. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412.
20. Gregory CR, Pratt RE, Huie P, et al. Effect of treatment with cyclosporin, FK506, rapamycin, MMF, or deoxyspergualin on vascular smooth muscle proliferation in vitro and in vivo. Transplant Proc 1993; 25: 770.
21. Obata T, Kashiwagi A, Maegawa H, et al. Insulin signaling and its regulation of system A amino acid uptake in cultured rat vascular smooth muscle cells. Circ Res 1996; 79: 1167.
22. Mohasci PJ, Tuller D, Hullinger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484.
23. Akselband Y, Harding MW, Nelson PA. Rapamycin inhibits spontaneous and bFGF driven proliferation of endothelial cells and fibroblasts. Transplant Proc 1991; 23: 2833.
24. Simm A, Nestler M, Hoppe V. PDGF-AA, a potent mitogen for cardiac fibroblasts from adult rats. J Mol Cell Cardiol 1997; 29: 357.
25. Nair R, Huang X, Shorthouse R, et al. Antiproliferative effect of rapamycin on growth factor stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997; 29: 614.
26. Gregory C, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation 1993; 55: 1409.
27. Morris RE, Cao W, Huang X, et al. Rapamycin inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon injured carotid arteries evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells. Transplant Proc 1995; 27: 430.
28. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and MMF reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655.
29. Poston RS, Billingham M, Grant Hoyt E, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100: 67.
30. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969.
31. Dodge I, Demirci G, Strom TB, Li XC. Rapamycin induces TGFβ production by lymphocytes. Transplantation 2000; 70: 1104.
32. Kharma AK. Mechanism of the combination immunosuppressive effects of Rapamycin with either cyclosporine or tacrolimus. Transplantation 2000; 70: 690.
33. Solez KM, Axelsen RA, Benediktsson H, et al. International standardisation of criteria for the diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
34. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
35. Bicknell GR, Shaw JA, Pringle JH, Furness PN. Amplification of specific mRNA from a single human renal glomerulus, with an approach to the separation of epithelial cell mRNA. J Pathol 1996; 180: 188.
36. Hall LL, Bicknell GR, Primrose L, Pringle JH, Shaw JA, Furness PN. Reproducibility in the quantification of m RNA levels by RT-PCR-ELISA and competitive RT-PCR-ELISA. Biotechniques 1998; 24: 652.
37. Weatherford TW. Staining of collagenous and non-collagenous structures with picrosirius red F3BA. J Med Sci 1972; 9: 383.
38. Nicholson ML, Bailey E, Williams S, Harris KPG, Furness PN. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 1999; 68: 236.
39. Hunsicker LG, Bennett LE. Design of trials of methods to reduce late renal allograft loss: the price of success. Kidney Int 1995; 48: S120.
40. Vankawala R, Kode RK, Damask AM, et al. Conversion from mycophenolate to rapamycin for acute and chronic rejection [Abstract]. Chicago: AST/ASTS, 2001.
41. Dimeny E, Fellstrom B. Metabolic abnormalities in renal transplant recipients. Risk factors and predictors of chronic graft dysfunction. Nephrol Dial Transplant 1997; 12: 21.
42. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration in the rat: evidence for pharmacokinetic interactions. J Ther Drug Monit 1998; 20: 123.
43. Saunders RN, Murphy GJ, Metcalfe MS, Kimber R, Nicholson ML. Rapamycin and reduced-dose cyclosporin produce effective immunosuppression for de novo renal transplant recipients [Abstract]. Chicago: AST/ ASTS, 2001.
44. Johnson WG, Kreis H, Oberbauer R, et al. Sirolimus (Rapamune) maintenance therapy permits early cyclosporin withdrawal resulting in improved renal function: 12-month results of the Tri-continental trial [Abstract]. Chicago: AST/ASTS, 2001.
45. Hricik DE. Improved renal function with Cyclosporin elimination in Sirolimus treated renal transplant recipients: one-year results from a phase II trial [Abstract]. The Rapamune Renal Function Study Group. Chicago: AST/ASTS, 2001.
46. Peraldi MN, Morelon E, Mamzer-Bruneel MN, Burke J, Kreis H. Renal function improvement after switch from calcineurin dependent drugs to Sirolimus in renal transplant recipients with chronic graft nephropathy [Abstract]. Rome: International Congress of the Transplantation Society, 2000.
47. Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70: 1244.
48. Ignotz RA, Endo T, Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem 1987; 158: 6443.
49. Border WA, Okuda S, Languino LR, Ruoslahti E. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 1992; 37: 689.
50. Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. Kidney Int 1992; 41: 1213.
51. Paul LC, Saito Y, Davidoff A, Benediktsson H. Growth factor transcripts in renal transplants. Am J Kidney Dis 1996; 28: 441.
52. Shihab FS, Tanner AM, Shao Y, Weffer MI. Expression of TGF-β1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996; 50: 1904.
53. Mannon RB, Kopp JB, Ruiz P, et al. Chronic rejection of mouse kidney allografts. Kidney Int 1999; 55: 1935.
54. Sharma VK, Bologa RM, Xu GP, et al. Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996; 49: 1297.
55. Suthanthiran M. Molecular analysis of human renal allografts: Differential intragraft gene expression during rejection. Kidney Int 1997; 58: S15.
56. Shin GT, Khanna AK, Ding R, Sharma VK, Lagman M, Suthanthiran M. In vivo expression of transforming growth factor β1 in humans. Stimulation by cyclosporine. Transplantation 1998; 65: 313.
57. Hyman AR, Sharma VK, Ding R, Lagman M, Suthanthiran M. The effect of rapamycin on TGFβ signal transduction in cultured mammalian cells [Abstract]. Chicago: AST/ASTS, 2001.
58. Xavier P, Oliveira JGG, Henriques C, et al. Cytokine changes with rapamycin in renal transplants [Abstract]. Rome: International Congress of the Transplantation Society, 2000.
59. Murphy GJ, Bicknell GR, Saunders RN, Metcalfe MS, Nicholson ML. Combined rapamycin/Neoral therapy effectively inhibits allograft vasculopathy in rat allografts but attenuates changes in profibrotic gene expression associated with rapamycin alone [Abstract]. Chicago: AST/ASTS, 2001.
60. Campbell SE, Janicki JS, Matsubara BB, Weber KT. Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am J Hypertens 1993; 6: 487.
61. Rubio CA, Porwit A. Quantitation of fibrosis in liver biopsies. Anal Quant Cytol Histol 1988; 10: 107.
62. Malkusch W, Rehn B, Bruch J. Advantages of Sirius Red staining for quantitative morphometric collagen measurements in lungs. Exp Lung Res 1995; 21: 67.
63. Valderrama R, Navarro S, Campo E, et al. Quantitative measurement of fibrosis in pancreatic tissue: evaluation of a colorimetric method. Int J Pancreatol 1991; 10: 23.
64. Nickerson P, Jeffery J, Gough J, et al. Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplantation 1999; 3: 257.